Paasa Logo
Eupraxia Pharmaceuticals Inc. logo
EPRXTSXMarket closedOpens 9:30am ET

Eupraxia Pharmaceuticals Inc.

CA$11.65Last updated
+CA$0.34 (3.01%)Past day
Timezone

Eupraxia Pharmaceuticals Inc. (TSX: EPRX) is trading at CA$11.65, about ₹788 at today's CAD/INR rate, as of 28 Sep 2026, 4:00 PM ET, up 3.01% today. Indian residents can buy Eupraxia Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:CA$11.10
Previous close:CA$11.31
Volume:67.54K

Today's low

CA$11.10

Today's high

CA$11.65

52 week low

CA$7.35

52 week high

CA$12.86

EPRX opened at CA$11.10, closed previously at CA$11.31, and has traded between CA$7.35 and CA$12.86 over the past 52 weeks.

About

Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.

Country
CA
CEO
James A. Helliwell
Exchange listed on
TSX
Industry
Biotechnology
Base currency
CAD
Full Time Employees
49
Sector
Healthcare
IPO date
09/03/2021

Key statistics

Avg. volume

68.91K

Market cap

CA$418.67M

P/E Ratio

-8.05

Price-to-sales ratio

0.00

Enterprise value

$244.51M

Free cash flow yield

-12.40%

Debt-to-equity ratio

0.01

Return on equity

-45.29%

ROIC

-43.07%

Beta

1.49

Dividend yield

0.00%

Last dividend

CA$0.00

Financial overview

Revenue

$0.00

Earnings per share

-$1.05

Free cash flow

-$29.65M

Net profit margin

0.00%

Gross margin

0.00%

EBITDA

-$38.86M

Revenue growth

—

Similar securities

This is not an investment recommendation

How to buy Eupraxia Pharmaceuticals from India

Indian residents can buy Eupraxia Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CAD.

  3. Search for Eupraxia Pharmaceuticals and place an order

    Find Eupraxia Pharmaceuticals by name or by its ticker, EPRX, and choose an order type. Eupraxia Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Eupraxia Pharmaceuticals position in CAD and INR. Eupraxia Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Eupraxia Pharmaceuticals from India

Trading and taxes when buying Eupraxia Pharmaceuticals from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneEupraxia Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Eupraxia Pharmaceuticals stock?

Yes. Eupraxia Pharmaceuticals (EPRX) has been listed on the Toronto Stock Exchange since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CAD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Eupraxia Pharmaceuticals share cost in rupees?

One Eupraxia Pharmaceuticals share is CA$11.65 — about ₹788 at a CAD/INR rate of 67.65 on 28 Sep 2026. Both the Eupraxia Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Eupraxia Pharmaceuticals from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

How are gains on Eupraxia Pharmaceuticals shares taxed in India?

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CAD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Eupraxia Pharmaceuticals price. Paasa issues a capital-gains statement for your return.

Does Eupraxia Pharmaceuticals pay a dividend?

No. Eupraxia Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Eupraxia Pharmaceuticals from India?

The Toronto Stock Exchange trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when Canada is on standard time. Orders can only execute during that window.

Do I have to declare Eupraxia Pharmaceuticals shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Eupraxia Pharmaceuticals holding, its cost and its closing value.

How do I sell Eupraxia Pharmaceuticals and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in CAD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.

Does the rupee rate affect what I make on Eupraxia Pharmaceuticals?

Yes. Eupraxia Pharmaceuticals is priced in CAD, so your rupee outcome combines the CAD move with the CAD/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.